Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua

Breuer, Elmar; Efferth, Thomas

doi:10.1007/s13659-014-0013-7

Cited by 32 publications

(14 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The animals were treated with various doses of 150 mg/day (3 capsules), 450 mg/day (2 capsules), 450 mg/day (3 capsules), and 450 mg/day (2 capsules). All the animals showed complete reduction with no tumor relapse [175].…”

Section: In Vivo Studies Of Anticancer Herbal Medicine: An Overviewmentioning

confidence: 80%

Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects

Khan

Ali

Khan³

et al. 2019

Biomolecules

247

118

View full text Add to dashboard Cite

The rising burden of cancer worldwide calls for an alternative treatment solution. Herbal medicine provides a very feasible alternative to western medicine against cancer. This article reviews the selected plant species with active phytochemicals, the animal models used for these studies, and their regulatory aspects. This study is based on a meticulous literature review conducted through the search of relevant keywords in databases, Web of Science, Scopus, PubMed, and Google Scholar. Twenty plants were selected based on defined selection criteria for their potent anticancer compounds. The detailed analysis of the research studies revealed that plants play an indispensable role in fighting different cancers such as breast, stomach, oral, colon, lung, hepatic, cervical, and blood cancer cell lines. The in vitro studies showed cancer cell inhibition through DNA damage and activation of apoptosis-inducing enzymes by the secondary metabolites in the plant extracts. Studies that reported in vivo activities of these plants showed remarkable results in the inhibition of cancer in animal models. Further studies should be performed on exploring more plants, their active compounds, and the mechanism of anticancer actions for use as standard herbal medicine.

show abstract

Section: In Vivo Studies Of Anticancer Herbal Medicine: An Overviewmentioning

confidence: 80%

Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects

Khan

Ali

Khan³

et al. 2019

Biomolecules

247

118

View full text Add to dashboard Cite

show abstract

“…Scopoletin is a constituent of Artemisia annua L. which is used for malaria treatment and also reveals activity towards cancer, schistosomasis and viral diseases [6,7,8,9,10,11]. We found high amounts of scopoletin in this plant, indicating that artemisinin may not be the only bioactive compound in A. annua [12]. Scopoletin is known for its cytotoxicity towards cancer cells [13,14,15].…”

Section: Introductionmentioning

confidence: 98%

Pharmacogenomics of Scopoletin in Tumor Cells

et al. 2016

Self Cite

View full text Add to dashboard Cite

Drug resistance and the severe side effects of chemotherapy necessitate the development of novel anticancer drugs. Natural products are a valuable source for drug development. Scopoletin is a coumarin compound, which can be found in several Artemisia species and other plant genera. Microarray-based RNA expression profiling of the NCI cell line panel showed that cellular response of scopoletin did not correlate to the expression of ATP-binding cassette (ABC) transporters as classical drug resistance mechanisms (ABCB1, ABCB5, ABCC1, ABCG2). This was also true for the expression of the oncogene EGFR and the mutational status of the tumor suppressor gene, TP53. However, mutations in the RAS oncogenes and the slow proliferative activity in terms of cell doubling times significantly correlated with scopoletin resistance. COMPARE and hierarchical cluster analyses of transcriptome-wide mRNA expression resulted in a set of 40 genes, which all harbored binding motifs in their promoter sequences for the transcription factor, NF-κB, which is known to be associated with drug resistance. RAS mutations, slow proliferative activity, and NF-κB may hamper its effectiveness. By in silico molecular docking studies, we found that scopoletin bound to NF-κB and its regulator IκB. Scopoletin activated NF-κB in a SEAP-driven NF-κB reporter cell line, indicating that NF-κB might be a resistance factor for scopoletin. In conclusion, scopoletin might serve as lead compound for drug development because of its favorable activity against tumor cells with ABC-transporter expression, although NF-κB activation may be considered as resistance factor for this compound. Further investigations are warranted to explore the full therapeutic potential of this natural product.

show abstract

“…An open-label pilot study of patients receiving artesunate for advanced cervical cancer suggested that it was well tolerated and improved symptoms ( Jansen et al, 2011 ). There has been a phase II trial on the activity of artesunate in non-resectable tumours of dogs ( Rutteman et al, 2013 ) and efficacy of extracts of A. annua in 5 veterinary sarcomas ( Breuer and Efferth, 2014 ). This study examines anti-CRC effects and tolerability of artesunate used as monotherapy in a rigorous study design.…”

Section: Introductionmentioning

confidence: 99%

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundArtesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects.AimTo determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC).MethodsThis was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome measure was the proportion of tumour cells undergoing apoptosis (significant if > 7% showed Tunel staining). Secondary immunohistochemical outcomes assessed these tumour markers: VEGF, EGFR, c-MYC, CD31, Ki67 and p53, and clinical responses.Findings20 patients (artesunate = 9, placebo = 11) completed the trial per protocol. Randomization groups were comparable clinically and for tumour characteristics. Apoptosis in > 7% of cells was seen in 67% and 55% of patients in artesunate and placebo groups, respectively. Using Bayesian analysis, the probabilities of an artesunate treatment effect reducing Ki67 and increasing CD31 expression were 0.89 and 0.79, respectively. During a median follow up of 42 months 1 patient in the artesunate and 6 patients in the placebo group developed recurrent CRC.InterpretationArtesunate has anti-proliferative properties in CRC and is generally well tolerated.

show abstract

Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua

Cited by 32 publications

References 71 publications

Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects

Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects

Pharmacogenomics of Scopoletin in Tumor Cells

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

Contact Info

Product

Resources

About